A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00672945
Recruitment Status : Terminated
First Posted : May 6, 2008
Last Update Posted : July 30, 2009
Information provided by:
Epix Pharmaceuticals, Inc.

Brief Summary:
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: PRX-03140 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Primary Purpose: Treatment
Official Title: Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
Study Start Date : April 2008
Estimated Primary Completion Date : January 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Donepezil

Arm Intervention/treatment
Experimental: PRX-03140 Drug: PRX-03140
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Alzheimer's Disease Assessment Scale-Cognitive subscale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Men or Women with a clinical diagnosis of Probable AD
  • MMSE score 12 to 22 inclusive
  • Age >50 and <90 years
  • Received at least 4 months of a stable dose of donepezil 10mg QD for AD
  • Brain CT or MRI scan Consistent with a primary diagnosis of AD within 24 months
  • Neurological examination without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)
  • No history or evidence of any other CNS disorder that could be interpreted as a cause of dementia
  • No diagnosis of vascular dementia
  • No history of significant psychiatric illness such as schizophrenia or bipolar affective disorder. Subjects with major depressive disorder on a stable dose of an antidepressant for >6 months may be eligible
  • No evidence of the following: current vitamin B12 deficiency, positive syphilis serology, positive HIV test, or abnormalities in thyroid function
  • No cognitive rehabilitation within 6 months of the study
  • Subject has a regular caregiver willing to attend all study visits
  • Signed informed consent by the subject (and legal guardian, if applicable)
  • No history of drug or alcohol abuse
  • No clinically significant laboratory abnormalities or medical history
  • No investigational drug within 30 days of Randomization
  • Cannot receive memantine within 2 months of enrollment
  • No other prescription acetylcholinesterase inhibitors for AD (other than donepezil) within 4 months of enrollment
  • No clinically significant ECG abnormalities or cardiac history
  • No history of uncontrolled seizure disorder within 12 months of enrollment
  • Cannot be taking MAO inhibitors, bupropion,fluoxetine, paroxetine, quinidine
  • No history of malignancy within 3 years of randomization
  • Women cannot be pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00672945

  Show 38 Study Locations
Sponsors and Collaborators
Epix Pharmaceuticals, Inc.

Responsible Party: Elkan R. Gamzu, PhD, EPIX Pharmaceuticals, Inc Identifier: NCT00672945     History of Changes
Other Study ID Numbers: Protocol 01340-202
First Posted: May 6, 2008    Key Record Dates
Last Update Posted: July 30, 2009
Last Verified: July 2009

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents